Last updated: May 26, 2026
Simvastatin supply is concentrated across (1) APIs made under GMP by established API manufacturers and (2) finished-dose tablet supply by branded and generic formulators. In practice, buyer access typically routes through API traders, CDMOs, or vertically integrated generic manufacturers that also hold branded ANDA supply chains.
What companies supply simvastatin API (active pharmaceutical ingredient)?
Simvastatin API is typically produced by chemical API manufacturers specializing in fermentation-derived or synthetic statin intermediates and then polished into GMP API for dosage-form makers. The commercial supplier base includes large-scale API producers and specialty statin API firms, with lots supplied to multiple downstream customers.
Common simvastatin API sourcing routes
- Direct from GMP API manufacturers to generic/tablet makers under supply agreements.
- Through API distributors that qualify lots for multiple finished-dose manufacturers.
- Via CDMO API-to-tablet value chains where the CDMO controls both stages and regulatory documentation.
Typical deliverables buyers request from simvastatin API suppliers
- DMF/ASMF linkage for intended regulatory submissions (US DMF, EU CEP, or equivalent).
- CoA, impurity profile, and residual solvent compliance.
- Particle size, polymorph/solid-state controls, and stability data.
- Supply continuity terms tied to batch release testing, change control, and site qualification.
Which suppliers make simvastatin tablets (finished dosage form) in the US?
Simvastatin tablets are supplied by both branded and generic manufacturers. Finished-dose suppliers normally support multiple strengths (commonly 5 mg, 10 mg, 20 mg, 40 mg) and offer bottle and commercial formats depending on channel.
Finished-dose supply chain characteristics
- Generic finished-dose manufacturers usually rely on qualified API from one or more GMP API sites.
- Multi-source API qualification is common to reduce supply disruption risk.
- Tablet manufacturing includes blending, compression, coating, and lot release analytics under cGMP.
Buyers typically screen for
- ANDA portfolio alignment by strength and label.
- Batch record traceability and deviation history.
- Pharmacopoeial compliance (USP/EP expectations for API and finished product).
What is the Orange Book status of simvastatin and how does it affect supplier choice?
Simvastatin is a widely marketed small-molecule product with generic availability and no meaningful reliance on current reference-product exclusivity for finished-dose sourcing. Supplier selection is driven less by patent exclusivity and more by ANDA ownership, facility readiness, and qualified API supply.
Orange Book implications for procurement
- Multiple ANDA suppliers exist, creating purchasing competition.
- Regulatory equivalence is usually less about molecule novelty and more about excipient choices and manufacturing comparability.
- Supplier risk is more tied to cGMP performance, supply continuity, and API lot quality than to data exclusivity.
Do simvastatin suppliers face any regulatory or quality constraints unique to statins?
Simvastatin is chemically stable relative to many labile small molecules, but it has impurity and solid-state control expectations. Suppliers are expected to manage:
- Impurity specification control during synthesis and purification.
- Stable polymorphic/solid-state behavior for both API and tablets.
- Robust dissolution performance and bioequivalence support for finished doses.
Quality dossiers buyers often require for qualification
- API analytical method package (or full cross-reference to US DMF/ASMF).
- Impurity profile (process and degradation impurities).
- Stability indicating data for API and finished product.
- Container-closure and storage condition controls.
Which simvastatin API manufacturers supply generic tablet makers and distributors?
At procurement level, the “best” supplier set is typically defined by:
- Proven GMP record in FDA inspections.
- Consistent ability to supply required strengths and packaging configurations.
- Demonstrated willingness to support DMF cross-referencing or regulatory filing requirements.
- On-time batch release and transparent change control.
Practical supplier landscape (how buyers map it)
- API manufacturers: qualified for US DMF/ASMF and EU filings.
- Tablet manufacturers: qualified for ANDA filings and commercial distribution.
- Distributors: mediate allocation when API supply is constrained.
How many suppliers typically exist for simvastatin API and tablets?
Simvastatin has a broad generic market, which usually translates into:
- Multiple finished-dose suppliers for each common strength.
- Multiple API sources that can feed qualified finished-dose manufacturing.
The number varies by geography and buyer qualification strictness. Buyers with established qualification programs often maintain at least two qualified API sources and at least two finished-dose suppliers per SKU to mitigate shortages.
What manufacturing/IP barriers can block simvastatin supplier onboarding?
For simvastatin, major procurement barriers are usually operational rather than core-molecule exclusivity:
- API site qualification delays (analytical comparability and impurity confirmation).
- DMF/ASMF cross-reference timing and change control constraints.
- Formulation or excipient differences that affect tablet dissolution and BE justification.
- Supply allocation during capacity constraints.
Common onboarding friction points
- Residual solvent and impurity specs that differ between suppliers.
- Solid-state characterization requirements (polymorph, particle size distribution).
- Stability commitments if the supplier changes a site, solvent, or purification step.
What does a simvastatin supplier contract usually cover?
Simvastatin supply agreements in the market typically address:
- Annual volumes by strength and packaging.
- Minimum order quantities and release schedules.
- Batch release criteria and right-to-reject terms.
- Change notifications for process, analytical methods, or suppliers.
- Quality agreement terms covering deviations, CAPA timelines, and audit rights.
How strong is the patent estate for simvastatin and does it constrain sourcing?
Simvastatin is off active composition-of-matter exclusivity long ago and is generally a mature generic market. Sourcing constraints are therefore not typically driven by current patent barriers. They are driven by:
- Facility qualification.
- Regulatory documentation alignment.
- Supply reliability and quality consistency.
What supplier risks matter most for simvastatin (shortages, quality, and batch failures)?
Buyer risk concentrates in:
- API supply continuity: shortages occur when a key API facility has maintenance, compliance actions, or raw material scarcity.
- Batch release failures: impurity spikes, dissolution variability, or stability out-of-spec events.
- Analytical method transfer: inability to match reference methods can slow release.
Mitigations buyers use
- Dual- or multi-sourcing API qualification.
- Contractually defined release testing windows.
- Safety stock and alternative packaging plans.
Key Takeaways
- Simvastatin supply is mature and typically available from multiple GMP API and finished-dose manufacturers, with supplier choice driven by qualification readiness, cGMP track record, and supply continuity rather than molecule exclusivity.
- API onboarding is often the critical path due to impurity controls, solid-state behavior, and regulatory documentation linkage (DMF/ASMF).
- Procurement contracts for simvastatin usually emphasize change control, batch release criteria, and audit/CAPA processes to manage quality and supply disruption risk.
FAQs
1) Who can qualify as an FDA supplier of simvastatin tablets for generics?
Manufacturers with ANDA approvals for the relevant strength(s) and packaging, operating under cGMP and supported by qualified API.
2) What API documentation is typically required to source simvastatin from a new supplier?
A regulatory dossier linkage (US DMF/ASMF or EU filing route), CoA, impurity profile, method cross-reference, and stability/solid-state evidence.
3) Do simvastatin tablets require polymorph control from the API supplier?
Yes. Solid-state characterization and consistent impurity/purity profiles are used to ensure dissolution and release stability across lots.
4) Can simvastatin be multi-sourced to reduce shortage risk?
Yes. Multi-source qualification for API and finished-dose manufacturing is common for continuity planning.
5) What are the most common reasons simvastatin lots get rejected during quality review?
Out-of-spec impurity levels, residual solvent issues, dissolution/deviation from specifications, or documentation gaps delaying batch release.
References (APA)
No sources were provided in the prompt, and no supplier-specific, company-specific, or regulatory-record-specific citations can be stated accurately without external lookup.
